{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:59:16Z","timestamp":1789574356058,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,16]]},"DOI":"10.7759\/cureus.92446","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T13:59:15Z","timestamp":1758031155000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Zilebesiran for the Management of Hypertension: An Updated Systematic Review and Meta-Analysis of Randomised Controlled Trials"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Raza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaudhry Zaid","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eymaan Riaz","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Jannat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Raffeh","family":"Basit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Jamshed","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hassan","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Waleed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"High blood pressure (hypertension). (2023). Accessed. June 15, 2025: https:\/\/my.clevelandclinic.org\/health\/diseases\/4314-hypertension-high-blood-pressure."},{"key":"ref2","unstructured":"Hypertension. (2023). Accessed. June 15, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension."},{"key":"ref3","unstructured":"high blood pressure. (2024). Accessed. June 15, 2025: https:\/\/www.mayoclinic.org\/diseases-conditions\/high-blood-pressure\/symptoms-causes\/syc-20373410."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363140-00001","article-title":"Current treatment of patients with hypertension: therapeutic implications of INSIGHT","volume":"63","author":"Taddei S","year":"2003","unstructured":"Taddei S, Ghiadoni L, Salvetti A. Current treatment of patients with hypertension: therapeutic implications of INSIGHT. Drugs. 2003, 63:1435-44. 10.2165\/00003495-200363140-00001","journal-title":"Drugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.77607","article-title":"Safety and efficacy of novel RNA interference therapeutic agent Zilebesiran in people with hypertension: a systematic review and meta-analysis","volume":"17","author":"Singh V","year":"2025","unstructured":"Singh V, Tewari J, Qidwai KA, Singh SK, Tewari A, Tewari V, Maheshwari A. Safety and efficacy of novel RNA interference therapeutic agent Zilebesiran in people with hypertension: a systematic review and meta-analysis. Cureus. 2025, 17:e77607. 10.7759\/cureus.77607","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.04.001","article-title":"siRNA takes a jab at hypertension","volume":"5","author":"Wulczyn KE","year":"2024","unstructured":"Wulczyn KE, Rhee EP. siRNA takes a jab at hypertension. Med. 2024, 5:383-5. 10.1016\/j.medj.2024.04.001","journal-title":"Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2016.17","article-title":"Structure and functions of angiotensinogen","volume":"39","author":"Lu H","year":"2016","unstructured":"Lu H, Cassis LA, Kooi CW, Daugherty A. Structure and functions of angiotensinogen. Hypertens Res. 2016, 39:492-500. 10.1038\/hr.2016.17","journal-title":"Hypertens Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02356-6","article-title":"Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis","volume":"24","author":"Abbas A","year":"2024","unstructured":"Abbas A, Hefnawy MT, Negida A. Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol. 2024, 24:243. 10.1186\/s12874-024-02356-6","journal-title":"BMC Med Res Methodol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai AS","year":"2023","unstructured":"Desai AS, Webb DJ, Taubel J, et al.. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023, 389:228-38. 10.1056\/NEJMoa2208391","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with Zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris GL","year":"2024","unstructured":"Bakris GL, Saxena M, Gupta A, et al.. RNA interference with Zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial. JAMA. 2024, 331:740-9. 10.1001\/jama.2024.0728","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.6681","article-title":"Add-on treatment with Zilebesiran for inadequately controlled hypertension: the KARDIA-2 randomized clinical trial","volume":"334","author":"Desai AS","year":"2025","unstructured":"Desai AS, Karns AD, Badariene J, et al.. Add-on treatment with Zilebesiran for inadequately controlled hypertension: the KARDIA-2 randomized clinical trial. JAMA. 2025, 334:46-55. 10.1001\/jama.2025.6681","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40279-023-01927-9","article-title":"The perils of misinterpreting and misusing \"publication bias\" in meta-analyses: an education review on funnel plot-based methods","volume":"54","author":"Afonso J","year":"2024","unstructured":"Afonso J, Ramirez-Campillo R, Clemente FM, B\u00fcttner FC, Andrade R. The perils of misinterpreting and misusing \"publication bias\" in meta-analyses: an education review on funnel plot-based methods. Sports Med. 2024, 54:257-69. 10.1007\/s40279-023-01927-9","journal-title":"Sports Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000962","article-title":"Zilebesiran: a novel RNA interference therapeutic for hypertension","volume":"Online ahead of print","author":"Maheta D","year":"2025","unstructured":"Maheta D, Shah F, Biba V, et al.. Zilebesiran: a novel RNA interference therapeutic for hypertension. Cardiol Rev. 2025, Online ahead of print:10.1097\/CRD.0000000000000962","journal-title":"Cardiol Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15010003","article-title":"Exploratory studies on RNAi-based therapies targeting angiotensinogen in hypertension: scoping review","volume":"15","author":"Menezes Junior AD","year":"2024","unstructured":"Menezes Junior AD, Nogueira TH, de Lima KB, de Oliveira HL, Botelho SM. Exploratory studies on RNAi-based therapies targeting angiotensinogen in hypertension: scoping review. J Pers Med. 2024, 15:10.3390\/jpm15010003","journal-title":"J Pers Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000002696","article-title":"Advancing hypertension management: the role of Zilebesiran as an siRNA therapeutic agent","volume":"87","author":"Siddiqui E","year":"2025","unstructured":"Siddiqui E, Siddiqui AH, Moeed A, Laique F, Najeeb H, Al Hasibuzzaman M. Advancing hypertension management: the role of Zilebesiran as an siRNA therapeutic agent. Ann Med Surg (Lond). 2025, 87:577-82. 10.1097\/MS9.0000000000002696","journal-title":"Ann Med Surg (Lond)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.21037\/actr-24-139","article-title":"Is Zilebesiran a novel effective and uniquely administered agent for an expanding therapeutic armamentarium for blood pressure control?","volume":"3","author":"Flack JM","year":"2025","unstructured":"Flack JM. Is Zilebesiran a novel effective and uniquely administered agent for an expanding therapeutic armamentarium for blood pressure control?. AME Clin Trials Rev. 2025, 3:1-4. 10.21037\/actr-24-139","journal-title":"AME Clin Trials Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/399190-efficacy-and-safety-of-zilebesiran-for-the-management-of-hypertension-an-updated-systematic-review-and-meta-analysis-of-randomised-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T13:59:16Z","timestamp":1758031156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/399190-efficacy-and-safety-of-zilebesiran-for-the-management-of-hypertension-an-updated-systematic-review-and-meta-analysis-of-randomised-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.92446","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,16]]}}}